There's no way in the world the FDA is not going to require several more years of clinical trials to study the efficacy and safety of an lsd derivative to treat adhd and opiod withdrawals. With such a low percentage of the float short as of 9/15, the timing of a 50% dilution is not surprising. Now it's htb, so only the whales will be able to get/open new short positions, not retail, and they'll ride this thing to $0.80 Why no bounce today? Not even a dead cat.
The good news is, they still have $170M on the shelf, regardless of where the stock trades. Not sure what their cash burn is, but that can probably keep them afloat for several more years while the FDA reviews things, albeit it will create substantially more dilution. They just went from 28M shares to 42M... with zero revenue We have experienced operating losses and cash outflows from operations since inception and will require ongoing financing to continue our research and development activities and we have not earned any revenue or reached successful commercialization of our products. Our future operations are dependent upon our ability to finance our cash requirements which will allow us to continue our research and development activities and the commercialization of our products. There can be no assurance that we will be successful in continuing to finance our operations. Attention Robinhood: buy buy buy!!!!
I am now. They burned $77M last quarter. With zero revenues, that $28M they are getting from this dilution won't last long. I'm just being 100% honest here. I have no dog in this fight. But.... This thing could go to zero. And it probably will. I don't care where or how high its been. We'll see though.
For sure. Well known from the get go. I was in very early. Out too early. Back in too early. This sector has tons of potential. Very risky.
Well g/l with it either way. It does have tons of potential, but from what I've read, the hurdle lies in the legality, Federal-wise, of the stuff they have in clinical trials. That's a hell of a hurdle to clear if the Feds won't even allow weed to be approved. Of course J&J got keto thru. But J&J has members of both houses of Congress in their back pocket.
MDMA NEW YORK, Oct. 4, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the initiation of a Phase 1 investigator-initiated trial led by MindMed collaborator Prof. Dr. Matthias Liechti at University Hospital Basel (UHB). The study aims to compare acute responses to R-MDMA, S-MDMA, and MDMA in healthy subjects. "MDMA is a racemic substance containing equal amounts of the enantiomers S-MDMA and R-MDMA," said Prof. Dr. Liechti, principal investigator of the trial. "Preclinical research indicates that S-MDMA mainly releases dopamine, norepinephrine, serotonin, and oxytocin while R-MDMA may act more directly on 5-HT2A receptors and release prolactin. Animal studies indicate that R-MDMA may have fewer adverse effects and have greater prosocial effects. But the acute effects of S- and R-MDMA have never been validly examined in a human study. We are excited for the opportunity to potentially validate these findings in healthy human subjects." Dr. Miri Halperin Wernli, Executive President of MindMed, added, "Although we know from animal studies that the two enantiomers act synergistically to produce the subjective effects of MDMA, this study represents an opportunity to validate the potential improved safety profile and prosocial effects of the R-enantiomer of MDMA. Preclinical studies of R-MDMA demonstrate its acute prosocial effects, while its diminished dopaminergic activity suggest that it will exhibit less stimulant activity, neurotoxicity, hyperthermia and abuse liability compared to racemic MDMA or the S-enantiomer. MindMed is developing MM-402 for the treatment of core symptoms of autism spectrum disorder (ASD), which is a developmental disorder characterized by atypical social communication and interactions, repetitive patterns of behavior and restricted interests. Despite its significant and growing prevalence, there are no therapies approved to treat the core symptoms of ASD. We look forward to exploring the exciting opportunities being unlocked by Dr. Liechti's research." The Phase 1 trial is a randomized, placebo-controlled, double-blind, 5-period crossover study. The trial plans to enroll 24 healthy subjects, who will receive R-MDMA (125 and 250mg), S-MDMA (125mg), MDMA (125mg), and a placebo. The primary outcome measures for this trial will assess acute subjective effects using the Visual Analog Scales (VAS) and the 5 Dimensions of Altered States of Consciousness (5D-ASC). Secondary endpoints will assess autonomic effects (blood pressure, heart rate, body temperature), mood on the days following the administration, endocrine effects, plasma concentration, and additional subjective effects (VAS, AMRS, SCQ, PIQ). More information about this trial is available at clinicaltrials.gov (identifier: NCT05277636) and at mindmed.co.
NEW YORK , Oct. 5, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc.(MMCWF) , , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of MindMed's management team will participate in the Cantor Fitzgerald Neurology & Psychiatry Conference, taking place at the Ritz Carlton, San Francisco, CA from October 6-7, 2022 Cantor Fitzgerald Neurology & Psychiatry Conference Format: Panel presentation and one-on-one investor meetings Panel Title: "Tripping our way to a new treatment paradigm for psychiatric disorders: intermittent therapy vs chronic treatment" Panel Date: Thursday, October 6, 2022 Panel Time: 12:10 p.m. PDT Location: Ritz Carlton, San Francisco, CA ___________________ Edit: lol ---> "Tripping our way to a new treatment paradigm"